PHROMPO 250mg film-coated tablets medication leaflet

L01EB01 gefitinib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

Gefitinib is a medication used for the treatment of non-small cell lung cancer, particularly in patients with epidermal growth factor receptor (EGFR) mutations. It is a tyrosine kinase inhibitor.

This medication works by blocking signals that promote the growth and division of cancer cells. It is taken orally, usually once daily, as directed by a doctor.

Common side effects include diarrhea, skin rash, nausea, and fatigue. In rare cases, severe reactions such as interstitial lung disease may occur.

It is important to follow your doctor's instructions closely and report any side effects or unusual symptoms. Regular monitoring is necessary to assess treatment effectiveness.

General data about PHROMPO 250mg

Substance: gefitinib

Date of last drug list: 01-04-2022

Commercial code: W67809003

Concentration: 250mg

Pharmaceutical form: film-coated tablets

Quantity: 30

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: ALKALOID-INT D.O.O. - SLOVENIA

Holder: ALKALOID-INT D.O.O. - SLOVENIA

Number: 13809/2021/02

Shelf life: 3 years